Photo of Chin Hur,  MD, MPH

Chin Hur, MD, MPH

Massachusetts General Hospital

Massachusetts General Hospital

Chin Hur, MD, MPH

Massachusetts General Hospital


  • Associate Professor, Medicine, Harvard Medical School
  • Director, GI Health Outcomes Research, Gastrointestinal Unit, Massachusetts General Hospital


Research Abstract

Dr. Hur's areas of clinical areas of interests include: gastroesophageal reflux disease (GERD), Barrett's esophagus, esophageal adenocarcinoma as well as gastrointestinal cancer screening. His research interest lies in outcomes research, specifically technology assessment with a focus on decision analysis and disease modeling, and the application of these methodologies to the management of cancers and pre-malignant states (e.g. dysplasia) in the gastrointestinal tract. This management includes the identification of clinical predictors, diagnostic algorithms, and the optimization of treatment.

Some of the representative projects that he has worked on include a Simulation Model of Esophageal Adenocarcinoma, a Markov Model of Duodenal Polyposis in Familial Adenomatous Polyposis (FAP), an analysis of the impact of the implementation of Virtual Colonoscopies for colorectal cancer (CRC) screening and the possible role for chemoprevention in cancer care.

Current Projects:

- Disease model (Markov Monte-Carlo) of Barrett's esophagus and esophageal adenocarcinoma, including the evaluation of new endoscopic therapies to determine if they are cost-effective

- Quality of life and patient preferences in Barrett's esophagus

- Cost-Effectiveness of cancer chemoprevention (e.g. aspirin and/or selective COX-2 inhibitors)

- Technology assessment of "Virtual Colonoscopy" or computed tomographic colonography


Powered by Harvard Catalyst
  • Huang HL, Leung CY, Saito E, Katanoda K, Hur C, Kong CY, Nomura S, Shibuya K. Effect and cost-effectiveness of national gastric cancer screening in Japan: a microsimulation modeling study. BMC Med 2020; 18:257. PubMed
  • Fong ZV, Chang DC, Hur C, Jin G, Tramontano A, Sell NM, Warshaw AL, Fernandez-Del Castillo C, Ferrone CR, Lillemoe KD, Qadan M. Variation in long-term oncologic outcomes by type of cancer center accreditation: An analysis of a SEER-Medicare population with pancreatic cancer. Am J Surg 2020; 220:29-34. PubMed
  • Omidvari AH, Ali A, Hazelton WD, Kroep S, Lee M, Naber SK, Lauren BN, Ostvar S, Richmond E, Kong CY, Rubenstein JH, Lansdorp-Vogelaar I, Luebeck G, Hur C, Inadomi J. Optimizing Management of Patients with Barrett's Esophagus and Low-grade or No Dysplasia Based On Comparative Modeling: Optimizing Barrett's esophagus management. Clin Gastroenterol Hepatol 2019. PubMed
  • Tramontano AC, Chen Y, Watson TR, Eckel A, Sheehan DF, Peters MLB, Pandharipande PV, Hur C, Kong CY. Pancreatic cancer treatment costs, including patient liability, by phase of care and treatment modality, 2000-2013. Medicine (Baltimore) 2019; 98:e18082. PubMed
  • Tramontano AC, Chen Y, Watson TR, Eckel A, Hur C, Kong CY. Esophageal cancer treatment costs by phase of care and treatment modality, 2000-2013. Cancer Med 2019; 8:5158-5172. PubMed
  • Bloom PP, Mojtahed A, Bethea ED, Knooihuizen SA, Choi J, Dienstag JL, Chung RT, Hur C. Computed Tomography Findings as a Novel Predictor of Alcohol-Associated Hepatitis Outcomes. Dig Dis Sci 2019. PubMed
  • Weaver DT, Lietz AP, Mercaldo SF, Peters MLB, Hur C, Kong CY, Wolpin BM, Megibow AJ, Berland LL, Knudsen AB, Pandharipande PV. Testing for Verification Bias in Reported Malignancy Risks for Side-Branch Intraductal Papillary Mucinous Neoplasms: A Simulation Modeling Approach. AJR Am J Roentgenol 2019; 212:596-601. PubMed
  • Yamamoto KN, Nakamura A, Liu LL, Stein S, Tramontano AC, Kartoun U, Shimizu T, Inoue Y, Asakuma M, Haeno H, Kong CY, Uchiyama K, Gonen M, Hur C, Michor F. Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies. PLoS ONE 2019; 14:e0215409. PubMed
  • Sheehan DF, Criss SD, Chen Y, Eckel A, Palazzo L, Tramontano AC, Hur C, Cipriano LE, Kong CY. Lung cancer costs by treatment strategy and phase of care among patients enrolled in Medicare. Cancer Med 2018. PubMed
  • Choi JG, Nipp RD, Tramontano A, Ali A, Zhan T, Pandharipande P, Dowling EC, Ferrone CR, Hong TS, Schrag D, Fernandez-Del Castillo C, Ryan DP, Kong CY, Hur C. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis. Oncologist 2018. PubMed
  • Nipp RD, Tramontano AC, Kong CY, Hur C. Patterns and predictors of end-of-life care in older patients with pancreatic cancer. Cancer Med 2018; 7:6401-6410. PubMed
  • Chu JN, Choi J, Ostvar S, Torchia JA, Reynolds KL, Tramontano A, Gainor JF, Chung DC, Clark JW, Hur C. Cost-effectiveness of immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. Cancer 2018. PubMed
  • Lin EC, Holub J, Lieberman D, Hur C. Low Prevalence of Suspected Barrett's Esophagus in Patients with Gastroesophageal Reflux Disease Without Alarm Symptoms. Clin Gastroenterol Hepatol 2018. PubMed
  • Tramontano AC, Nipp R, Kong CY, Yerramilli D, Gainor JF, Hur C. Hospice use and end-of-life care among older patients with esophageal cancer. Health Sci Rep 2019; 1:e76. PubMed
  • Bethea ED, Samur S, Kanwal F, Ayer T, Hur C, Roberts MS, Terrault N, Chung RT, Chhatwal J. Cost-effectiveness of Transplanting HCV-Infected Livers into Uninfected Recipients with Preemptive Antiviral Therapy. Clin Gastroenterol Hepatol 2018. PubMed
  • Tramontano AC, Nipp R, Mercaldo ND, Kong CY, Schrag D, Hur C. Survival Disparities by Race and Ethnicity in Early Esophageal Cancer. Dig Dis Sci 2018. PubMed
  • Peters MLB, Eckel A, Mueller PP, Tramontano AC, Weaver DT, Lietz A, Hur C, Kong CY, Pandharipande PV. Progression to pancreatic ductal adenocarcinoma from pancreatic intraepithelial neoplasia: Results of a simulation model. Pancreatology 2018. PubMed
  • Thein HH, Jembere N, Thavorn K, Chan KKW, Coyte PC, de Oliveira C, Hur C, Earle CC. Estimates and predictors of health care costs of esophageal adenocarcinoma: a population-based cohort study. BMC Cancer 2018; 18:694. PubMed
  • Hur C, Zhan T, Thrift AP, Vaughan TL, Feuer EJ. Lorenz Curves and Gini Coefficient Analyses Indicate Inefficiencies in Esophageal Adenocarcinoma Screening. Clin Gastroenterol Hepatol 2018. PubMed
  • Nipp R, Tramontano AC, Kong CY, Pandharipande P, Dowling EC, Schrag D, Hur C. Disparities in cancer outcomes across age, sex, and race/ethnicity among patients with pancreatic cancer. Cancer Med 2018; 7:525-535. PubMed
  • Bethea E, Chen Q, Hur C, Chung RT, Chhatwal J. Response to Treatment of Acute HCV Cost-Effective but at What Price? Hepatology 2018. PubMed
  • Eschenfeldt PC, Kartoun U, Heberle CR, Kong CY, Nishioka NS, Ng K, Kamarthi S, Hur C. Analysis of factors associated with extended recovery time after colonoscopy. PLoS ONE 2018; 13:e0199246. PubMed
  • Chu JN, Choi J, Tramontano A, Morse C, Forcione D, Nishioka NS, Abrams JA, Rubenstein JH, Kong CY, Inadomi JM, Hur C. Surgical vs Endoscopic Management of T1 Esophageal Adenocarcinoma: A Modeling Decision Analysis. Clin Gastroenterol Hepatol 2017. PubMed
  • Lockwood R, Ozanne E, Hur C, Yachimski P. Patient decision-making and clinical outcomes following endoscopic therapy or esophagectomy for Barrett's neoplasia. Endosc Int Open 2017; 5:E1128-E1135. PubMed
  • Samur S, Kues B, Ayer T, Roberts MS, Kanwal F, Hur C, Donnell DMS, Chung RT, Chhatwal J. Cost-Effectiveness of Pre versus Post Liver Transplant Hepatitis C Treatment with Direct-Acting Antivirals. Clin Gastroenterol Hepatol 2017. PubMed
  • Tramontano AC, Sheehan DF, Yeh JM, Kong CY, Dowling EC, Rubenstein JH, Abrams JA, Inadomi JM, Schrag D, Hur C. The Impact of a Prior Diagnosis of Barrett's Esophagus on Esophageal Adenocarcinoma Survival. Am J Gastroenterol 2017. PubMed
  • Heberle CR, Omidvari AH, Ali A, Kroep S, Kong CY, Inadomi JM, Rubenstein JH, Tramontano AC, Dowling EC, Hazelton WD, Luebeck EG, Lansdorp-Vogelaar I, Hur C. Cost-Effectiveness of Screening Patients with Gastroesophageal Reflux Disease for Barrett's Esophagus With a Minimally Invasive Cell Sampling Device. Clin Gastroenterol Hepatol 2017. PubMed
  • Yeh JM, Tramontano AC, Hur C, Schrag D. Comparative effectiveness of adjuvant chemoradiotherapy after gastrectomy among older patients with gastric adenocarcinoma: a SEER-Medicare study. Gastric Cancer 2017. PubMed
  • Kroep S, Heberle CR, Curtius K, Kong CY, Lansdorp-Vogelaar I, Ali A, Wolf WA, Shaheen NJ, Spechler SJ, Rubenstein JH, Nishioka NS, Meltzer SJ, Hazelton WD, van Ballegooijen M, Tramontano AC, Gazelle GS, Luebeck EG, Inadomi JM, Hur C. Impact of Radiofrequency Ablation Treatment of Barrett's Esophagus on Esophageal Adenocarcinoma: A Comparative Modeling Analysis. Clin Gastroenterol Hepatol 2017. PubMed
  • Lubitz C, Ali A, Zhan T, Heberle C, White C, Ito Y, Miyauchi A, Gazelle GS, Kong CY, Hur C. The thyroid cancer policy model: A mathematical simulation model of papillary thyroid carcinoma in The U.S. population. PLoS ONE 2017; 12:e0177068. PubMed
  • Yachimski P, Hur C. Endoscopic therapy versus surgery for T1 colon cancer: defining model clinical practice. Gastrointest Endosc 2016; 84:995-996. PubMed
  • Samur S, Klebanoff M, Banken R, Pratt DS, Chapman R, Ollendorf DA, Loos AM, Corey K, Hur C, Chhatwal J. Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis. Hepatology 2016. PubMed
  • Chhatwal J, Samur S, Kues B, Ayer T, Roberts MS, Kanwal F, Hur C, Donnell DM, Chung RT. Optimal Timing of Hepatitis C Treatment for Patients on the Liver Transplant Waiting List. Hepatology 2016. PubMed
  • Chhatwal J, He T, Hur C, Lopez-Olivo MA. Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection are Cost Saving. Clin Gastroenterol Hepatol 2016. PubMed
  • Chhatwal J, Wang X, Ayer T, Kabiri M, Chung RT, Hur C, Donohue JM, Roberts MS, Kanwal F. Hepatitis C Disease Burden in the United States in the Era of Oral Direct-Acting Antivirals. Hepatology 2016. PubMed
  • Pandharipande PV, Heberle C, Dowling EC, Kong CY, Tramontano A, Perzan KE, Brugge W, Hur C. Targeted Screening of Individuals at High Risk for Pancreatic Cancer: Results of a Simulation Model. Radiology 2015; 278:306. PubMed
  • Hur HC, King LP, Klebanoff MJ, Hur C, Ricciotti HA. Fibroid morcellation: a shared clinical decision tool for mode of hysterectomy. Eur J Obstet Gynecol Reprod Biol 2015; 195:122-127. PubMed
  • Simon RE, Pearson SD, Hur C, Chung RT. Tackling the hepatitis C cost problem: A test case for tomorrow's cures. Hepatology 2015. PubMed
  • Protano MA, Xu H, Wang G, Polydorides AD, Dawsey SM, Cui J, Xue L, Zhang F, Quang T, Pierce MC, Shin D, Schwarz RA, Bhutani MS, Lee M, Parikh N, Hur C, Xu W, Moshier E, Godbold J, Mitcham J, Hudson C, Richards-Kortum RR, Anandasabapathy S. Low-Cost High-Resolution Microendoscopy for the Detection of Esophageal Squamous Cell Neoplasia: An International Trial. Gastroenterology 2015. PubMed
  • Hazelton WD, Curtius K, Inadomi JM, Vaughan TL, Meza R, Rubenstein JH, Hur C, Luebeck EG. The Role of Gastroesophageal Reflux and Other Factors during Progression to Esophageal Adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2015; 24:1012-23. PubMed
  • Hur C, Choi SE, Kong CY, Wang GQ, Xu H, Polydorides AD, Xue LY, Perzan KE, Tramontano AC, Richards-Kortum RR, Anandasabapathy S. High-resolution microendoscopy for esophageal cancer screening in China: A cost-effectiveness analysis. World J Gastroenterol 2015; 21:5513-23. PubMed
  • Chak A, Buttar NS, Foster NR, Seisler DK, Marcon NE, Schoen R, Cruz-Correa MR, Falk GW, Sharma P, Hur C, Katzka DA, Rodriguez LM, Richmond E, Sharma AN, Smyrk TC, Mandrekar SJ, Limburg PJ, . Metformin does not reduce markers of cell proliferation in esophageal tissues of patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2015. PubMed
  • Pandharipande PV, Heberle C, Dowling EC, Kong CY, Tramontano A, Perzan KE, Brugge W, Hur C. Targeted screening of individuals at high risk for pancreatic cancer: results of a simulation model. Radiology 2015; 275:177-87. PubMed
  • Yeh JM, Hur C, Ward Z, Schrag D, Goldie SJ. Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis. Gut 2015. PubMed
  • Swan JS, Kong CY, Hur C, Halpern EF, Itauma O, Williams O, Motazedi T, Lee JM. Comparing morbidities of testing with a new index: screening colonoscopy versus core-needle breast biopsy. J Am Coll Radiol 2015; 12:295-301. PubMed
  • Yachimski P, Hur C. Evidence-based endoscopic management of Barrett's esophagus. Gastroenterol Rep (Oxf) 2015. PubMed
  • Yachimski P, Wani S, Givens T, Howard E, Higginbotham T, Price A, Berman K, Hosford L, Katcher PM, Ozanne E, Perzan K, Hur C. Preference of endoscopic ablation over medical prevention of esophageal adenocarcinoma by patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2014. PubMed
  • Yasuda K, Choi SE, Nishioka NS, Rattner DW, Puricelli WP, Tramontano AC, Kitano S, Hur C. Incidence and predictors of adenocarcinoma following endoscopic ablation of Barrett's esophagus. Dig Dis Sci 2014. PubMed
  • Kong CY, Kroep S, Curtius K, Hazelton WD, Jeon J, Meza R, Heberle CR, Miller MC, Choi SE, Lansdorp-Vogelaar I, van Ballegooijen M, Feuer EJ, Inadomi JM, Hur C, Luebeck EG. Exploring the recent trend in esophageal adenocarcinoma incidence and mortality using comparative simulation modeling. Cancer Epidemiol Biomarkers Prev 2014. PubMed
  • Choi SE, Perzan KE, Tramontano AC, Kong CY, Hur C. Statins and aspirin for chemoprevention in Barrett's esophagus: results of a cost-effectiveness analysis. Cancer Prev Res (Phila Pa) 2014. PubMed
  • Shaheen NJ, Hur C. Garlic, silver bullets, and surveillance upper endoscopy for Barrett's esophagus. Gastroenterology 2013; 145:273-6. PubMed
  • Hoshida Y, Villanueva A, Sangiovanni A, Sole M, Hur C, Andersson KL, Chung RT, Gould J, Kojima K, Gupta S, Taylor B, Crenshaw A, Gabriel S, Minguez B, Iavarone M, Friedman SL, Colombo M, Llovet JM, Golub TR. Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology 2013; 144:1024-30. PubMed
  • Hur C, Miller M, Kong CY, Dowling EC, Nattinger KJ, Dunn M, Feuer EJ. Trends in esophageal adenocarcinoma incidence and mortality. Cancer 2013; 119:1149-58. PubMed
  • Ananthakrishnan AN, Korzenik JR, Hur C. Can mucosal healing be a cost-effective endpoint for biologic therapy in Crohn's disease? A decision analysis. Inflamm Bowel Dis 2013. PubMed
  • Ladabaum U, Brill JV, Sonnenberg A, Shaheen NJ, Inadomi J, Wilcox CM, Park WG, Hur C, Pasricha PJ. How to value technological innovation: a proposal for determining relative clinical value. Gastroenterology 2012. PubMed
  • Yeh JM, Hur C, Schrag D, Kuntz KM, Ezzati M, Stout N, Ward Z, Goldie SJ. Contribution of H. pylori and smoking trends to US incidence of intestinal-type noncardia gastric adenocarcinoma: a microsimulation model. PLoS Med. 2013; 10:e1001451. PubMed
  • Knudsen AB, Hur C, Gazelle GS, Schrag D, McFarland EG, Kuntz KM. Rescreening of persons with a negative colonoscopy result: results from a microsimulation model. Ann Intern Med 2012; 157:611-20. PubMed
  • Falk GW, Buttar NS, Foster NR, Ziegler KL, Demars CJ, Romero Y, Marcon NE, Schnell T, Corley DA, Sharma P, Cruz-Correa MR, Hur C, Fleischer DE, Chak A, Devault KR, Weinberg DS, Della'Zanna G, Richmond E, Smyrk TC, Mandrekar SJ, Limburg PJ, . A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus. Gastroenterology 2012; 143:917-26.e1. PubMed
  • Hur C, Choi SE, Rubenstein JH, Kong CY, Nishioka NS, Provenzale DT, Inadomi JM. The cost effectiveness of radiofrequency ablation for Barrett's esophagus. Gastroenterology 2012; 143:567-75. PubMed
  • Omer ZB, Ananthakrishnan AN, Nattinger KJ, Cole EB, Lin JJ, Kong CY, Hur C. Aspirin protects against Barrett's esophagus in a multivariate logistic regression analysis. Clin Gastroenterol Hepatol 2012. PubMed
  • Choi SE, Hur C. Screening and surveillance for Barrett's esophagus: current issues and future directions. Curr Opin Gastroenterol 2012; 28:377-81. PubMed
  • Ananthakrishnan AN, Hur C, Korzenik JR. Certolizumab pegol compared to natalizumab in patients with moderate to severe Crohn's disease: results of a decision analysis. Dig Dis Sci 2012. PubMed
  • Ananthakrishnan AN, Hur C, Juillerat P, Korzenik JR. Strategies for the prevention of postoperative recurrence in Crohn's disease: results of a decision analysis. Am J Gastroenterol 2011. PubMed
  • Kong CY, Nattinger KJ, Hayeck TJ, Omer ZB, Wang YC, Spechler SJ, McMahon PM, Gazelle GS, Hur C. The impact of obesity on the rise in esophageal adenocarcinoma incidence: estimates from a disease simulation model. Cancer Epidemiol Biomarkers Prev 2011. PubMed
  • Ho W, Broughton DE, Donelan K, Gazelle GS, Hur C. Analysis of barriers to and patients' preferences for CT colonography for colorectal cancer screening in a nonadherent urban population. AJR Am J Roentgenol 2010; 195:393-7. PubMed
  • Yeh JM, Ho W, Hur C. Cost-effectiveness of endoscopic surveillance of gastric ulcers to improve survival. Gastrointest Endosc 2010; 72:33-43. PubMed
  • Yeh JM, Hur C, Kuntz KM, Ezzati M, Goldie SJ. Cost-effectiveness of treatment and endoscopic surveillance of precancerous lesions to prevent gastric cancer. Cancer 2010; 116:2941-53. PubMed
  • Yachimski P, Lee RA, Tramontano A, Nishioka NS, Hur C. Secular Trends in Patients Diagnosed with Barrett's Esophagus. Dig Dis Sci 2010; 55:960-6. PubMed
  • Huang ES, Gazelle GS, Hur C. Consensus Guidelines in the Management of Branch Duct Intraductal Papillary Mucinous Neoplasm: A Cost-Effectiveness Analysis. Dig Dis Sci 2010; 55:852-60. PubMed
  • Hur C, Hayeck TJ, Yeh JM, Richards EB, Spechler SJ, Gazelle GS, Kong CY. Development, calibration, and validation of a U.S. white male population-based simulation model of esophageal adenocarcinoma. PLoS ONE 2010; 5:e9483. PubMed
  • Greenblatt WH, Hur C, Knudsen AB, Evans JA, Chung DC, Gazelle GS. Cost-effectiveness of prophylactic surgery for duodenal cancer in familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev 2009; 18:2677-84. PubMed
  • Hur C,Broughton DE,Kong CY,Ozanne EM,Richards EB,Truong T,Gazelle GS. Patient Preferences for the Chemoprevention of Colorectal Cancer. Dig Dis Sci 2009; 54:2207-14. PubMed
  • Yachimski P,Nishioka NS,Richards E,Hur C. Treatment of Barrett's esophagus with high-grade dysplasia or cancer: predictors of surgical versus endoscopic therapy. Clin Gastroenterol Hepatol 2008; 6:1206-11. PubMed
  • Pandharipande PV,Harisinghani MG,Ozanne EM,Specht MC,Hur C,Lee JM,Gazelle GS. Staging MR lymphangiography of the axilla for early breast cancer: cost-effectiveness analysis. AJR Am J Roentgenol 2008; 191:1308-19. PubMed
  • Hur C,Broughton DE,Ozanne E,Yachimski P,Nishioka NS,Gazelle GS. Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus. Am J Gastroenterol 2008; 103:2432-42. PubMed
  • Pandharipande PV, Gervais DA, Mueller PR, Hur C, Gazelle GS. Radiofrequency Ablation versus Nephron-sparing Surgery for Small Unilateral Renal Cell Carcinoma: Cost-effectiveness Analysis. Radiology 2008; 248:169-78. PubMed
  • Yeh JM,Kuntz KM,Ezzati M,Hur C,Kong CY,Goldie SJ. Development of an empirically calibrated model of gastric cancer in two high-risk countries. Cancer Epidemiol Biomarkers Prev 2008; 17:1179-87. PubMed
  • Hur C, Yachimski P. How useful is histologic confirmation of intestinal metaplasia in patients with long-segment Barrett's esophagus? Nat Clin Pract Gastroenterol Hepatol 2008; 5:140-1. PubMed
  • Choi MY, Lauwers GY, Hur C, Willett CG, Chung DC. Microsatellite instability is frequently observed in rectal cancer and influenced by neoadjuvant chemoradiation. Int J Radiat Oncol Biol Phys 2007; 68:1584. PubMed
  • Hur C. Esophageal capsule endoscopy for Barrett's esophagus screening: a hard pill to swallow? Clin Gastroenterol Hepatol 2007; 5:307-9. PubMed
  • Hur C, Chung DC, Schoen RE, Gazelle GS. The management of small polyps found by virtual colonoscopy: results of a decision analysis. Clin Gastroenterol Hepatol 2007; 5:237-44. PubMed
  • Schoen RE, Hur C. What is the clinical importance of small polyps with regard to colorectal cancer screening? Nat Clin Pract Gastroenterol Hepatol 2006; 3:488-9. PubMed
  • Hur C, Wittenberg E, Nishioka NS, Gazelle GS. Quality of life in patients with various Barretts esophagus associated health states. Health Qual Life Outcomes 2006; 4:45. PubMed
  • Siegel CA, Hur C, Korzenik JR, Gazelle GS, Sands BE. Risks and Benefits of Infliximab for the Treatment of Crohn's Disease. Clin Gastroenterol Hepatol 2006; 4:1017-24; quiz 976. PubMed
  • Hur C, Chan AT, Tramontano AC, Gazelle GS. Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs. Ann Pharmacother 2006; 40:1052-63. PubMed
  • Hur C, Wittenberg E, Nishioka NS, Gazelle GS. Patient preferences for the management of high-grade dysplasia in Barrett's esophagus. Dig Dis Sci 2005; 50:116-25. PubMed
  • Swan JS, Hur C, Lee P, Motazedi T, Donelan K. Responsiveness of the testing morbidities index in colonoscopy. Value Health 2013; 16:1046-53. PubMed